Psoriatic arthritis
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.
Vaneet K Sandhu, MD vksandhumd
4 years 7 months ago
Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador https://t.co/f0o8m5K0d2 https://t.co/Wm0sQDUeY1
Dr. Tom Appleton and Dr. Peter Nash Highlight OA and PsA Studies
Dr. Janet Pope interviews Dr. Tom Appleton and Dr. Peter Nash about several osteoarthritis and psoriatic arthritis studies presented at the 2020 ACR annual meeting.
Mid-Meeting Recap: Psoriatic Arthritis
On Saturday, November 7th, Drs. Cush and Kavanaugh discuss psoriatic arthritis reports from ACR 2020 with Dr. Eric Ruderman and Dr. Robert Chao.
Enthesitis in PsA: Dr. Robert Chao
Dr. Robert Chao reviews abstracts #1853, #1552, #1543 and #2021 presented at the 2020 ACR annual meeting.
Robert B Chao, MD doctorRBC
4 years 7 months ago
Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu
Who has more comorbidities? Dr. Janet Pope
Dr. Janet Pope reviews abstract #1466 presented at the 2020 ACR annual meeting. Who has more comorbidities: OA, Gout, RA or PsA?
Robert B Chao, MD doctorRBC
4 years 7 months ago
Deucravacitinib TYK2i for PsA
Phase2b 16wk, Double-blind, Placebo, RCT
⬆️ACR20/50/70 response vs. PBO
⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO
*⃣No serious AE
@RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/9Klu2aeEj2
Dr. John Cush RheumNow
4 years 7 months ago
Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial of 203 PsA patients showed wk 16 significant improvement in ACR20/50/70, enthesitis, SPARC scores. #ACR20 Abstr#L03 https://t.co/LGokmmlyrc
Robert B Chao, MD doctorRBC
4 years 7 months ago
Abs#1562 Detected subclinical synovitis/tenosynovitis in 37.2% of PsA pts in clinical remission. Do you routinely use MRI to monitor disease activity in your PsA patients? @RheumNow #ACR20
Olga Petryna DrPetryna
4 years 7 months ago
@rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i
k dao KDAO2011
4 years 7 months ago
No need to stop Tofa w/the flu?
👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB.
👉Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar.
Abstr#L04 #ACR20 @rheumnow #ACRBest
https://t.co/rZXKRVl7uK
A New Pathway in Psoriatic Arthritis: Dr. Eric Ruderman
Dr. Ruderman discusses a new pathway - the use of deucravacitinib - for the treatment of psoriatic arthritis (abstracts L03) at the ACR 2020 annual meeting.
sheila RHEUMarampa
4 years 7 months ago
#Curcumin for PsA & RA?🤔
Results suggest curcumin's efficacy on pt's perceived symptom alleviation & poss correlation w/ dose and length of tx. @RheumNow #ACR20 abs1230 https://t.co/xUxUEW02ww
Dr. Antoni Chan synovialjoints
4 years 7 months ago
Lots of interesting studies in Spondyloarthritis including AxSpA and PsA at #ACR20 @RheumNow https://t.co/tIyqyMdmTf
Poster Hall